Cellular Technology (CTL) announces the availability of cryopreserved human peripheral blood mononuclear cells (PBMC)
The thawed human peripheral blood mononuclear cells (PBMC) display better than 90% viability and when tested for peptide or protein antigen-induced T cell recall responses in cytokine Elispot assays, the frequencies and per-cell cytokine productivities of the thawed cells approximate 100% of the fresh PBMC.
CTL's cryopreserved PBMC are available either uncharacterised or characterised for HLA-type low/high resolution, antigen reactivity, age, gender, ethnicity, blood type, and vaccination status for vaccinia, TB, and hepatitis B.
Custom orders are also available.
Not only can they be used for validation and protocol set up purposes, but they are also an excellent tool for internal controls for clinical trials.
Ready access to such PBMC, of the same donor and the same bleed, should facilitate human immunological research and assay standardisation within and between laboratories.
All donors are routinely screened to be negative for the following infectious pathogens HIV-1/HIV-2, hepatitis B virus (HBV) and hepatitis C virus (HCV).
The procedures for collecting PBMC from donors are in accordance with the general accepted ethical standards.
